RAS proteins directly activate PI3-kinases. Mice bearing a germline mutation in the RAS
binding domain of the p110α subunit of PI3-kinse are resistant to the development of RAS …

Ras proteins are key regulators of signalling cascades, controlling many processes such as
proliferation, differentiation and apoptosis. Mutations in these proteins or in their effectors …

RAS proteins are small GTPases known for their involvement in oncogenesis: around 25%
of human tumors present mutations in a member of this family. RAS operates in a complex …

Ras proteins signal through direct interaction with a number of effector enzymes, including
type I phosphoinositide (PI) 3-kinases. Although the ability of Ras to control PI 3-kinase has …

Direct interaction of RAS with the PI3K p110α subunit mediates RAS-driven tumor
development: however, it is not clear how p110α/RAS-dependant signaling mediates …

In contrast to its growth-inhibitory effect on primary mesenchymal cells, RAS oncogene
activation induces a proliferative phenotype in normal human thyroid epithelial cells in vitro …

RAS proteins are key signaling switches essential for control of proliferation, differentiation,
and survival of eukaryotic cells. RAS proteins are mutated in 30% of human cancers. In …

Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the
p110-α catalytic subunit (encoded by PIK3CA). They are most frequently observed in two …

Adenocarcinoma of the lung, a leading cause of cancer death, frequently displays
mutational activation of the KRAS proto-oncogene but, unlike lung cancers expressing …

The phosphoinositide 3-kinase (PI3K) and RAS oncoproteins are activated in many major
tumor types and control linked signaling pathways. An inhibitor of PI3K is now shown to …